General
Preferred name
GEMCITABINE
Synonyms
GEMCITABINE HYDROCHLORIDE ()
Gemzar, LY-188011 ()
Gemzar ()
Gemcitabine HCl ()
LY 188011 hydrochloride ()
NSC 613327 ()
LY188011 ()
Gemcitabine HCl (Gemzar) ()
LY-188011, NSC 613327 ()
NSC 613327,LY-188011 HCl ()
Gemcitabine (LY-188011) ()
Gemcitabine (LY-188011) HCl ()
Gemcitabine-13C,15N2 (hydrochloride) ()
Gemcitabine (Hydrochloride) ()
Infugem ()
Gemcitabine (as hydrochloride) ()
LY-188011 HYDROCHLORIDE ()
LY188011 HYDROCHLORIDE ()
Gemcitabina ()
LY-188011 ()
NSC-613327 ()
P&D ID
PD003524
CAS
95058-81-4
103882-84-4
122111-03-9
2757566-59-7
Tags
available
drug
nuisance
Approved by
PMDA
FDA
First approval
1996
Drug indication
Neoplasm
Solid tumour/cancer
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Gemcitabine is a nucleoside analogue chemotherapeutic. Chemically, the hydrogen atoms on the 2' carbon of deoxycytidine are replaced by fluorine atoms. (GtoPdb)
PRICE 29
PRICE 29
DESCRIPTION inhibitor of DNA replication; inhibitor of ribonucleotide reductase, thymidylate synthetase, and cytidine monophosphate (UMP-CMP) kinase (Informer Set)
DESCRIPTION Gemcitabine is a nucleoside metabolic inhibitor used as adjunct therapy in the treatment of certain types of ovarian cancer, non-small cell lung carcinoma, metastatic breast cancer, and as a single agent for pancreatic cancer. (Enamine Bioactive Compounds)
DESCRIPTION Gemcitabine (LY188011) is a synthetic cytosine nucleoside derivative and an inhibitor of DNA synthesis. Gemcitabine has antitumor and antimetabolic activities. Gemcitabine induces autophagy and apoptosis. (TargetMol Bioactive Compound Library)
DESCRIPTION Inhibits DNA synthesis and function. Inhibits DNA topoisomerase II (Tocris Bioactive Compound Library)
DESCRIPTION Gemcitabine hydrochloride (LY 188011 hydrochloride) is a synthetic cytosine nucleoside derivative and an inhibitor of DNA synthesis. Gemcitabine has antitumor and antimetabolic activities. Gemcitabine induces autophagy and apoptosis. (TargetMol Bioactive Compound Library)
Cell lines
683
Organisms
10
Compound Sets
34
A Collection of Useful Nuisance Compounds (CONS) for Interrogation of Bioassay Integrity
AdooQ Bioactive Compound Library
A11434
A10423
Axon Medchem Screening Library
3233
Cayman Chemical Bioactives
11690
9003096
22560
ChEMBL Approved Drugs
CHEMBL888
CHEMBL1637
ChEMBL Drugs
CHEMBL888
CHEMBL1637
Concise Guide to Pharmacology 2017/18
4793
Concise Guide to Pharmacology 2019/20
4793
Concise Guide to Pharmacology 2021/22
4793
Concise Guide to Pharmacology 2023/24
4793
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00441
DrugBank Approved Drugs
DB00441
DrugCentral
1283
DrugCentral Approved Drugs
1283
DrugMAP
DMSE3I7
DrugMAP Approved Drugs
DMSE3I7
Enamine Bioactive Compounds
EBC-11028
Enamine BioReference Compounds
Guide to Pharmacology
4793
Informer Set
411863
LINCS compound set
10252-101
10252-999
NCATS Inxight Approved Drugs
B76N6SBZ8R
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Nuisance compounds in cellular assays
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Gemcitabine(Gemzar)
Gemcitabine-Hydrochloride(Gemzar)
TargetMol Bioactive Compound Library
T0251
T6069
The Spectrum Collection
Tocris Bioactive Compound Library
3259
Welcome Trust Cancer Drugs
135
External IDs
105
Properties
(calculated by RDKit )
Molecular Weight
263.07
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
3
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
1
cLogP
-1.29
TPSA
110.6
Fraction CSP3
0.56
Chiral centers
3.0
Largest ring
6.0
QED
0.61
Structural alerts
1
Genotoxic
Nuisance compounds
Related compounds
Custom attributes
(extracted from source data)
Target
CMPK1
RRM1
TYMS
CMPK1, RRM1, RRM2, TYMS
DNA synthesis inhibitor
Apoptosis related,Autophagy,DNA/RNA Synthesis,Nucleoside Analog/Antimetabolite
Autophagy,DNA/RNA Synthesis,Nucleoside Analog/Antimetabolite
DNA synthesis
Nucleoside antimetabolite/analog
Compound status
FDA
Pathway
DNA replication
Apoptosis
Autophagy
Cell Cycle/Checkpoint
DNA Damage/DNA Repair
Primary Target
DNA, RNA and Protein Synthesis
MOA
DNA/RNA Synthesis
Inhibitor
Ribonucleotide Reductase inhibitor
DNA Damaging Agent
Member status
member
Indication
ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer
Therapeutic Class
Anticancer Agents
Nuisance MOA
Genotoxic
Targets
Equilibrative nucleoside transporter 1
Source data